The Corporate History of the Ferozsons Group began in 1894, when its Founder Maulvi Ferozuddin Khan established the Ferozsons publishing house. From the outset, our founder’s corporate vision involved playing a meaningful role in the education and health of the underprivileged population of the sub-continent. Consequently, Ferozsons Laboratories Limited was created in 1954 as one of the first pharmaceutical manufacturing facilities in the fledgling state of Pakistan. The company commenced operations in 1956, and in 1960 became the first Pakistani pharmaceutical company to be lister on the Karachi Stock Exchange. We have a consistent track record of financial performance, and are a 6-time recipient of the Karachi Stock Exchange's 'KSE Top 25 Companies Award.'
Through our range of branded generics and in-licensed products , we have attained market leadership in the areas of cardiology , oncology, gastroenterology, dermatology and anti-infective markets in the Pakistan. These products are now being exported to markets in Asia and Africa, and we are actively seeking export opportunities in other markets. Ferozsons is the Pakistan marketing and distribution partner for the Boston Scientific Corporation, USA for its range of cardiac and peripheral products and interventional devices. This partnership will allow us to further strengthen our channels in cardiology , oncology, and G.I. We offer principals an excellent manufacturing, marketing and distribution platform for launching their products in the Pakistan market. Our cGMP compliant production facility in Nowshera is ISO 9001 certified and we are fully equipped with state of the art manufacturing and testing equipment. The facility consists of independent sections, each with its own dedicated air handling system to avoid cross-contamination between different classes of drugs being manufactured. Our production capabilities include the manufacturing of tablets, capsules, syrups, suspensions, creams and ointments. Our facility control laboratory is among the best equipped in the industry and possesses Malver Particle Size Analyzers, High Performance Liquid Chromatographs (HPLC), Gas Chromatograph (GC), Fourier Transfer-IR Spectrophotometer and UV-Visible spectrometers, in addition to dissolution, disintergration, hardness and friability testers. In 2012, the Company undertook a major expansion in its manufacturing, adding a new production wing for the production of solid dosage forms. The new wing will be operational in early 2013.
